Sugi Predict

Sugi Predict / Compounds / SCHEMBL3343124

SCHEMBL3343124

SCHEMBL3343124

O=Cc1cccc(S(=O)(=O)N2CCOCC2)c1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ HTT P42858 1/20 0.59
▸ TSHR P16473 2/20 0.57
▸ RECQL P46063 1/20 0.57
▸ HPGD P15428 1/20 0.54
▸ MEN1 O00255 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ LMNA P02545 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ POLB P06746 3/20 0.53
▸ GAA P10253 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29533339 1.00 ALDH1A1 (0.59) ALDH1A1KDM4EHTTTSHRRECQL
SCHEMBL15652183 0.86 ALDH1A1 (0.65) ALDH1A1HTTTSHRMEN1KMT2A
SCHEMBL1003525 0.84 ALDH1A1 (0.63) ALDH1A1HTTTSHRMEN1KMT2A
SCHEMBL15651824 0.82 PKM (0.56) ALDH1A1HTTTSHRMEN1KMT2A
SCHEMBL15650298 0.82 POLB (0.61) HTTTSHRLMNASMN1; SMN2POLB
SCHEMBL16888223 0.81 ALDH1A1 (0.52) ALDH1A1KDM4EHTTTSHRRECQL
SCHEMBL20568836 0.81 ALDH1A1 (0.52) ALDH1A1KDM4EHTTTSHRRECQL
SCHEMBL847277 0.81 POLB (0.69) ALDH1A1KDM4EHTTTSHRMEN1
SCHEMBL29257268 0.79 ALDH1A1 (0.45) ALDH1A1HTTTSHRHPGDMEN1
SCHEMBL1196165 0.78 TSHR (0.63) ALDH1A1KDM4EHTTTSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 — — US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 — — US disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 — — US disclosed
WO-2023201012-A1 IKZF2 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-10-19 — — WO disclosed
WO-2023201012-A1 IKZF2 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-10-19 — — WO disclosed
CN-116457339-A Tricyclic compounds degrading novel substrates for medical treatment C4医药公司 2023-07-18 — — CN disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed
CN-110015984-A Substituted (E)-N '-(1- phenylethylene) benzoyl hydrazine analog as histone demethylase inhibitor 犹他大学研究基金会 2019-07-16 — — CN disclosed
CN-105555784-B Substituted (E) -N' - (1-phenylethylene) benzoyl hydrazine analogs as histone demethylase inhibitors 犹他大学研究基金会 2019-03-15 — — CN disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 — — US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 — — US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
US-20110312945-A1 CRTH2 MODULATORS IRONWOOD PHARMACEUTICALS, INC. 2011-12-22 — — US disclosed
WO-2010039982-A1 CRTH2 MODULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2010-04-08 — — WO disclosed
US-20050256159-A1 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors ASTRAZENECA AB (SE) 2005-11-17 — — US disclosed
EP-1556349-A1 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS Astrazeneca AB (SE) 2005-07-27 — — EP disclosed
WO-2004033427-A1 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS ASTRAZENECA AB (SE) 2004-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK ALDH1A1 3674/4885KDM4E 1409/4885HTT 3171/4885
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 ALDH1A1 4344/4885KDM4E 674/4885HTT 685/4885
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 ALDH1A1 2267/4885KDM4E 791/4885HTT 19/4885
US-20110312945-A1 CRTH2 MODULATORS HRH2, HRH1, NR1H2 ALDH1A1 851/4885KDM4E 4506/4885HTT 4858/4885
US-20050256159-A1 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors HSD11B1, HSD3B1, P4HA1 ALDH1A1 14/4885KDM4E 1277/4885HTT 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.